Renal transplantation is considered the standard of care for end stage renal disease patients. Supernumerary renal veins,
Renal graft rupture is a rare but a dreaded complication of kidney transplant. It has been most frequently seen in association with severe acute rejection, severe acute tubular necrosis and renal Vein Thrombosis. Many patients reach ESRD without an established vascular access and start dialysis through femoral venous access. Case study by Sanjay Kolte et al. highlights the unusual cause for graft rupture from iliofemoral vein thrombophlebitis (secondary to femoral vein cannulation for dialysis access) and also regarding changing trend in management of graft rupture by graft repair in preference to nephrectomy.
Posttransplant lymphoproliferative disorder (PTLD) is recognized as potentially one of the most devastating complications of organ transplantation. Disease may be nodal or extranodal, localized or widely disseminated. These disorders range from reactive, polyclonal plasmacytic hyperplasia to monomorphic clonal cell proliferation originating from T cells or B cells including plasma cells. The treatment of PTLD remains a challenge. Currently, there is no unifying consensus that dictates the specific treatment approaches that should be undertaken for all categories of patients.
Probably the first case report of multifocal extramedullary plasmacytoma which presented after 14 years of renal trans- With the use of potent immunosuppressive agents the incidence of acute rejection has fallen dramatically over time. When acute rejection occurs, it is an important clinical problem. Early episodes (occurring within 60 days of engraftment) may have a major effect on allograft survival. Acute rejection episodes are also the major predictor of the occurrence of chronic allograft nephropathy, which is responsible for most death-censored graft loss after the first year.
Original research by Mehrotra S et al. highlights the importance of panel reactive antibody and donor specific antibody in identifying patients at higher risk of rejection and added value in risk stratification in addition to CDC cross match.
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